

Syndecan 1 (D4Y7H) Rabbit mAb (PE Conjugate)

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
FC-FP	H	Endogenous	Rabbit IgG	#P18827	6382

Product Usage Information**Application**

Flow Cytometry (Fixed/Permeabilized)

Dilution

1:50

Storage

Supplied in PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA. Store at 4°C. Do not aliquot the antibodies. Protect from light. Do not freeze.

Specificity/Sensitivity

Syndecan 1 (D4Y7H) Rabbit mAb (PE Conjugate) recognizes endogenous levels of multimeric forms of syndecan 1 protein. The unconjugated antibody cross-reacts with proteins of unknown origin between 46-60 kDa in some cell lines by western blot analysis.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala294 of human syndecan 1 protein.

Description

This Cell Signaling Technology antibody is conjugated to phycoerythrin (PE) and tested in-house for direct flow cytometry analysis in human cells. This antibody is expected to exhibit the same species cross-reactivity as the unconjugated Syndecan 1 (D4Y7H) Rabbit mAb #12922.

Background

Syndecans are a family of type 1 transmembrane heparan sulfate proteoglycans comprising four members in mammals (SDC1-4) (1) encoded by four syndecan genes. Syndecans are involved in embryonic development, tumorigenesis, and angiogenesis (2). The extracellular domain harbors attachment sites for heparan sulfate and chondroitin sulfate chains, facilitating interaction with an array of proteins, including a plethora of growth factors. In addition, the hydrophobic C-terminal intracellular domain can interact with proteins containing a PDZ domain (2). These interactions place syndecans as important integrators of membrane signaling (3). Syndecans undergo proteolytic cleavage causing the release of their extracellular domain (shedding), converting the membrane-bound proteins into soluble molecular effectors (4).

Syndecan 1 (SDC1) is a specific marker for plasmacytic differentiation in hematologic disorders (5-7). This cell surface proteoglycan is also expressed in normal epithelial cells and tissues as well as various types of cancer tissues (8-11). The extracellular shed form of syndecan 1 remains soluble or accumulates in the extracellular matrix where it binds growth factors, cytokines and other extracellular matrix proteins (12,13). This binding activates signaling of bound growth factors or cytokines, which results in enhanced tumor growth, dissemination, angiogenesis, and osteolysis (14-17). As a result, the level of syndecan 1 protein and its shed form may serve as prognostic factors for a list of malignancies (6,18,19). Syndecan 1 has recently been found to be a critical mediator of macropinocytosis in pancreatic cancer (20).

Background References

1. Couchman, J.R. (2003) *Nat Rev Mol Cell Biol* 4, 926-37.
2. Multhaupt, H.A. et al. (2009) *J Physiol Pharmacol* 60 Suppl 4, 31-8.
3. Zimmermann, P. and David, G. (1999) *FASEB J* 13 Suppl, S91-S100.
4. Manon-Jensen, T. et al. (2010) *FEBS J* 277, 3876-89.
5. Chilosi, M. et al. (1999) *Mod Pathol* 12, 1101-6.
6. Seidel, C. et al. (2000) *Blood* 95, 388-92.
7. O'Connell, F.P. et al. (2004) *Am J Clin Pathol* 121, 254-63.
8. Inki, P. and Jalkanen, M. (1996) *Ann Med* 28, 63-7.
9. Matsumoto, A. et al. (1997) *Int J Cancer* 74, 482-91.
10. Conejo, J.R. et al. (2000) *Int J Cancer* 88, 12-20.
11. Zellweger, T. et al. (2003) *Prostate* 55, 20-9.
12. Bayer-Garner, I.B. et al. (2001) *Mod Pathol* 14, 1052-8.
13. Ramani, V.C. et al. (2013) *FEBS J* 280, 2294-306.
14. Derksen, P.W. et al. (2002) *Blood* 99, 1405-10.
15. You, W.K. and McDonald, D.M. (2008) *BMB Rep* 41, 833-9.
16. Ramani, V.C. et al. (2011) *J Biol Chem* 286, 6490-9.
17. Aragão, A.Z. et al. (2012) *PLoS One* 7, e43521.
18. Joensuu, H. et al. (2002) *Cancer Res* 62, 5210-7.

Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Applications Key	FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key	H: Human
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	<p>Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.</p> <p>Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.</p>